"Little research has been done on the efficacy of GLP-1 drugs like Ozempic when prescribed in smaller doses, but that hasn't stopped the craze from catching on. People are turning to microdosed GLP-1s to manage their weight, stave off side effects and to make the medications more affordable on a long term basis. For telehealth companies cashing in on off-brand formulations of popular weight loss drugs, microdosing is an option they're eager to pitch."
"Compounded versions of drugs like Novo Nordisk's semaglutide (Ozempic, Wegovy) and Eli Lilly's tirzepatide (Zepbound, Mounjaro) proliferated over the last few years due to a shortage of their name brand counterparts. With those shortages officially over in the U.S. - and exact copies of those drugs now banned - companies that sell compounded GLP-1s are getting creative to get around the rules."
Microdosing refers to taking sub-clinical doses of GLP-1 weight-loss drugs such as semaglutide and tirzepatide. Little research exists on efficacy or safety of these smaller doses, yet many people use microdosed GLP-1s to manage weight, reduce side effects, and lower long-term costs. Telehealth companies and compounding pharmacies sell off-brand or customized formulations to meet demand. Shortages of name-brand drugs drove proliferation of compounded versions; with shortages over and exact copies banned, sellers now modify formulations to remain lawful. These compounded options are not subject to the same safety measures and regulations as name-brand drugs.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]